Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

RAPT Therapeutics, Inc. (RAPT)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
17.07-0.31 (-1.78%)
At close: 04:00PM EST
16.27 -0.80 (-4.69%)
After hours: 06:34PM EST
Advertisement

RAPT Therapeutics, Inc.

561 Eccles Avenue
South San Francisco, CA 94080
United States
650 489 9000
https://www.rapt.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees94

Key Executives

NameTitlePayExercisedYear Born
Dr. Brian Russell Wong M.D., Ph.D.CEO, Pres & Director783kN/A1972
Mr. Rodney K. B. YoungCFO, Principal Accounting Officer & Sec.561.91kN/A1963
Dr. William HoChief Medical Officer564.44kN/A1966
Steve Young Ph.D.VP of TechnologyN/AN/AN/A
Dr. Dirk G. Brockstedt Ph.D.Chief Scientific OfficerN/AN/A1969
Ms. Gwen R. CarscaddenChief HR OfficerN/AN/A1961
Dr. Paul KassnerSr. VP of Quantitative & Computational BiologyN/AN/A1967
Dr. David WustrowSr. VP of Drug Discovery & Preclinical Devel.N/AN/A1959
Ms. Jennifer NicholsonSr. VP of Regulatory Affairs & Quality AssuranceN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Corporate Governance

RAPT Therapeutics, Inc.’s ISS Governance QualityScore as of November 28, 2022 is 7. The pillar scores are Audit: 6; Board: 6; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement